BioSpace News Archive

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today that it has received a notice (the “Notice”) from Cboe Canada (“Cboe”) indicating that Awakn is not in compliance with Section 3.01(3) of Cboe’s Listing Manual. Awakn has 90 days to address the non-compliance.

The global narcolepsy therapeutics market size reached USD 3.3 billion in 2022 and is projected to surpass around USD 6.90 billion by 2032, expanding at a CAGR of 7.7% from 2023 to 2032.

Applied UV, Inc. (NASDAQ: AUVI), a leader in global food security, air quality, and specialty building solutions today announced preliminary financial results for the third quarter and nine months ended September 30, 2023, and reiterated its previous guidance of approximately $45 million in revenue for 2023.

RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today reported financial results for the third quarter ended September 30, 2023 and provided an update on key corporate initiatives.

ALX Oncology Holdings Inc., an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, reported financial results and business highlights for the third quarter ended September 30, 2023.

Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant bacterial infections, announced financial results for the third quarter ended September 30, 2023, and provided a business update.

Eyenovia, Inc. announced its financial and operating results for the third quarter ended September 30, 2023.

Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the third quarter of 2023.